About Us:
The Team Behind Innovations in Diabetes Care
Abvance: Reimagining Diabetes Therapy with Science and Empathy
For too long, diabetes patients have been told to accept the risks of hypoglycemia as just another part of their treatment. But at Abvance, we believe that “good enough” isn’t good enough anymore. Every day, millions of people live in fear of dangerous blood sugar crashes, and we’re here to change that.
Our journey began in the Cherrington Lab at Vanderbilt University, where groundbreaking research revealed the powerful potential of combining insulin with glucagon in a stable formulation. This innovative approach has the potential to provide a hypoglycemia safety net, and our lead program, ABV102, is now backed by preliminary clinical data.
But what truly sets us apart isn't just our science – it's our deep personal connection to diabetes care. Our team of industry veterans, including leaders from Pfizer, Amylin Pharmaceuticals, Lilly, and Beta Bionics, brings both world-class expertise and genuine empathy to our mission. With our solution now positioned for full scale clinical development, we're closer than ever to transforming diabetes care.
Ready to be part of this revolution in insulin therapy? Discover how our innovative approach could eliminate the fear of hypoglycemia and set a new standard in diabetes care.
What Sets Us Apart
- Breakthrough Technology: molar ratio mechanism of action can provide an additional set of tools to manage diabetes including the lead program, ABV102, designed to reduce hypoglycemic risk for people taking mealtime insulin
- De-Risked Development: With a human proof-of-principle study under our belt already, Abvance has critical data demonstrating the scientific basis for the bet
- Trusted Leadership: Our experienced team brings decades of successful drug development and commercialization experience specifically in diabetes care
Our Team: Leaders in Diabetes Innovation
Edward Raskin, JD
Chief Executive Officer and Chairman of the Board
Ed has a longstanding passion for developing new treatments for diabetes. As a co-founder of Beta Bionics, Ed brings crucial expertise in medical device and biotech strategy. His dual background in law and business development, enhanced by his Harvard Business School training, strengthens our strategic planning and regulatory approach. Ed holds a JD from the University of California at Berkeley and a Corporate Directors Certificate from Harvard Business School
David Maggs, MD FRCP
Co-Founder, Chief Medical Officer, and Board Member
With over three decades at the intersection of endocrinology and pharmaceutical innovation, David brings unparalleled expertise in developing breakthrough diabetes treatments. His leadership roles at Warner Lambert, Pfizer, and Amylin Pharmaceuticals have shaped revolutionary therapies. At Abvance, he's driving our mission to make insulin therapy safer by combining deep clinical understanding with commercial vision. David holds an MBBS from the University of London and has been a practicing endocrinologist for decades.
Gibb Clarke, MBA
Chief Financial Officer
A veteran innovator in medical technology with over 20 years of experience, Gibb has successfully raised more than $400M in investment capital. His track record of successful exits, including Blockade Medical and Pulsar Vascular, combined with his experience as CFO at Beta Bionics, guides our financial strategy and investment approach. Gibb holds an MBA from Duke University Fuqua School of Business
Veena Rao, PhD, MBA
Chief Operating Officer
Veena brings over 25 years of expertise in drug development,medical technology, and diabetes algorithms. Her experiences at Lilly, and as former Chief Commercial Officer at Beta Bionics provide a deep understanding of the diabetes market and needs of patients, healthcare providers, caregivers, and payers. Veena holds a PhD in Chemical Engineering from Stanford University and an MBA from the Darden School of Business at the University of Virginia.
Michael Nguyen, MSc
Vice President of Development
With 20 years of pharmaceutical and drug delivery expertise, Michael's experience spans from discovery to commercialization at industry leaders like Merck and Catalent. His specialized knowledge in peptide development and regulatory affairs drives our technical strategy and ensures efficient development pathways. Mike holds an M.Sc. in Pharmaceutical Chemistry from Lehigh University.
Scientific Board of Advisors
Alan Cherington, PhD
Professor, Molecular Physiology and Biophysics Jacquelyn A. Turner and Dr. Dorothy J. Turner Chair in Diabetes Research, Medicine
Vanderbilt University
Soumitra Ghosh, PhD
Pioneering Protein Chemist
Amylin Pharmaceuticals, and Bristol Myers Squibb
Bruce Bode, MD
Atlanta Diabetes Associates
Clinical Associate Professor, Emory University GA
John Beals, PhD
Pharmaceutical Protein Chemist
Former Distinguished Research Scientist at Eli Lilly
All information on this web site relates to investigational new drugs which are limited by Federal law to investigational use only. Abvance does not make any claims to safety or efficacy as to any investigational product. No product discussed on this web site has been approved by any regulatory agency as safe or effective. The purpose of this web site is to provide information to potential industry partners and potential institutional investors.
Website & Branding by Mile End Digital